Z0011标准外乳腺癌患者腋窝手术降阶梯综述
本综述回顾了多项改变实践的随机临床试验,探讨Z0011标准外乳腺癌患者(如全乳切除、>2枚前哨淋巴结阳性、影像学检出淋巴结转移等)的腋窝手术降阶梯策略,重点讨论保腋窝的当前最佳实践。
要点
- Z0011排除全乳切除、>2枚前哨淋巴结阳性及影像学检出淋巴结转移者,导致指南不明确。
- 后续试验纳入更高肿瘤负荷患者,比较前哨淋巴结活检±腋窝放疗与腋窝淋巴结清扫。
- 对Z0011标准外患者,需依据后续试验结果个体化选择腋窝处理方式。
核心结论
- 对于Z0011标准外的乳腺癌患者,腋窝手术降阶梯的决策需参考后续临床试验结果,目前最佳实践尚待明确。
研究设计与样本
- 本综述总结了多项随机临床试验,这些试验纳入了比Z0011更高疾病负荷的患者,比较前哨淋巴结活检±腋窝放疗与腋窝淋巴结清扫。
主要发现
- Z0011试验显示临床T1-2、1-2枚前哨淋巴结阳性且接受保乳治疗的患者可安全免除腋窝淋巴结清扫。
- Z0011因排除全乳切除、>2枚前哨淋巴结阳性及影像学检出淋巴结转移患者而受到批评,导致指南不明确。
关键数值与推荐
- Z0011标准:临床T1-2肿瘤、1-2枚前哨淋巴结阳性、接受 upfront 保乳治疗。
临床怎么用
- 对于Z0011标准外患者,应依据后续试验证据个体化评估腋窝手术降阶梯的可行性。
局限性
- 本综述为叙述性回顾,未提供原始研究数据或定量合并分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past 2 decades, axillary surgical management for breast cancer patients has been reshaped after several practice-changing randomized clinical trials provided evidence to support the de-escalation of axillary surgery, specifically the omission of axillary lymph node dissection, for patients with positive axillary lymph nodes. One such practice-changing trial was the American College of Surgeons Oncology Group Z0011 trial, which showed that patients with clinical T1-2 breast tumors and limited nodal disease (1-2 positive sentinel lymph nodes) who underwent upfront breast-conserving therapy could be safely spared the morbidity of axillary lymph node dissection. American College of Surgeons Oncology Group Z0011 has been criticized as several important groups were excluded, such as patients who underwent a mastectomy, patients with >2 positive sentinel lymph nodes, or patients with imaging-detected lymph node metastases. These exclusions have led to unclear guidelines and very difficult management decisions for many patients with breast cancer who are just outside the Z0011 criteria. Several subsequent trials that investigated sentinel lymph node biopsy alone or sentinel lymph node biopsy plus axillary radiation versus axillary lymph node dissection enrolled patients with higher volumes of disease than American College of Surgeons Oncology Group Z0011, such as mastectomy patients or patients with >2 positive sentinel lymph nodes. The goal of this review is to describe the findings of these trials and to discuss the current best practices regarding axillary management in patients who are candidates for upfront surgery but were excluded from American College of Surgeons Oncology Group Z0011, with a particular focus on patients undergoing mastectomy, patients with >2 positive sentinel lymph nodes, patients with large or multifocal tumors, and patients with imaging-detected biopsy-proven lymph node metastases.
引用
- Giannakou A, Gooch J, Gergelis KR, et al. De-escalation of axillary surgery in patients outside Z0011 criteria. Surgery. 2023. PMID: 37156648. doi:10.1016/j.surg.2023.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。